Abstract
In a seminal report in 1999, Schenk and colleagues demonstrated that vaccination of a mouse model of Alzheimers disease (AD) with amyloid-β1-42 peptide (Aβ1-42) and adjuvant resulted in striking mitigation of AD-like pathology – giving rise to the field of AD immunotherapy. Later studies confirmed this result in other mouse models of AD and additionally showed cognitive improvement after Aβ vaccination. Based on these results, early developmental clinical trials ensued to immunize AD patients with Aβ1-42 plus adjuvant (so-called “active” Aβ immunotherapy; trade name AN-1792; Elan Pharmaceuticals, Dublin, Ireland). However, the phase IIa trial was halted after 6 % of patients developed aseptic meningoencephalitis. Despite occurrence of this adverse event, many individuals demonstrated high serum antibody titres to Aβ and histological evidence of clearance of the hallmark AD pathology, β-amyloid plaques. While raising justifiable safety concerns, these important results nonetheless demonstrated the feasibility of the active Aβ immunotherapy approach. This review focuses on alternative approaches to active Aβ vaccination that are currently in various stages of development – from pre-clinical studies in animal models to current clinical trials. Specifically, the focus is on those strategies that target inflammatory and immune aspects of AD, and can therefore be classified as immunotherapeutic in a broad sense.
Keywords: Alzheimer's disease, vaccination, AN-1792, immune, immunization, inflammation, cytokine
CNS & Neurological Disorders - Drug Targets
Title: Alternative Aβ Immunotherapy Approaches for Alzheimers Disease
Volume: 8 Issue: 2
Author(s): Terrence Town
Affiliation:
Keywords: Alzheimer's disease, vaccination, AN-1792, immune, immunization, inflammation, cytokine
Abstract: In a seminal report in 1999, Schenk and colleagues demonstrated that vaccination of a mouse model of Alzheimers disease (AD) with amyloid-β1-42 peptide (Aβ1-42) and adjuvant resulted in striking mitigation of AD-like pathology – giving rise to the field of AD immunotherapy. Later studies confirmed this result in other mouse models of AD and additionally showed cognitive improvement after Aβ vaccination. Based on these results, early developmental clinical trials ensued to immunize AD patients with Aβ1-42 plus adjuvant (so-called “active” Aβ immunotherapy; trade name AN-1792; Elan Pharmaceuticals, Dublin, Ireland). However, the phase IIa trial was halted after 6 % of patients developed aseptic meningoencephalitis. Despite occurrence of this adverse event, many individuals demonstrated high serum antibody titres to Aβ and histological evidence of clearance of the hallmark AD pathology, β-amyloid plaques. While raising justifiable safety concerns, these important results nonetheless demonstrated the feasibility of the active Aβ immunotherapy approach. This review focuses on alternative approaches to active Aβ vaccination that are currently in various stages of development – from pre-clinical studies in animal models to current clinical trials. Specifically, the focus is on those strategies that target inflammatory and immune aspects of AD, and can therefore be classified as immunotherapeutic in a broad sense.
Export Options
About this article
Cite this article as:
Town Terrence, Alternative Aβ Immunotherapy Approaches for Alzheimers Disease, CNS & Neurological Disorders - Drug Targets 2009; 8 (2) . https://dx.doi.org/10.2174/187152709787847306
DOI https://dx.doi.org/10.2174/187152709787847306 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research
Current Drug Targets Therapeutic Options for the Treatment of 2019-Novel Coronavirus in India: A Review
Coronaviruses An Overview of Interleukin-17A and Interleukin-17 Receptor A Structure, Interaction and Signaling
Protein & Peptide Letters Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System
Current Pharmaceutical Design CCR1 Antagonists: What Have We Learned From Clinical Trials
Current Topics in Medicinal Chemistry Interleukin-21 in Immune and Allergic Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Role of α -Crystallin B in Regulation of Stress Induced Cardiomyocyte Apoptosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Internal Ribosome Entry Site Elements in Eukaryotic Genomes
Current Genomics QSAR Study on a Series of Aryl Carboxylic Acid Amide Derivatives as Potential Inhibitors of Dihydroorotate Dehydrogenase (DHODH)
Medicinal Chemistry Role of Renin-Angiotensin System in Inflammation, Immunity and Aging
Current Pharmaceutical Design Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Editorial [Hot Topic: Anti-Neuroinflammatory Effects of Psychopharmaceuticals: Further than Monoamine Modulators (Guest Editor: Sadayuki Hashioka)]
Mini-Reviews in Medicinal Chemistry MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry Radiolabeled Compounds in Diagnosis of Infectious and Inflammatory Disease
Current Pharmaceutical Design Current Biological Therapies for Inflammatory Bowel Disease
Current Pharmaceutical Design Magnetic Nanoparticles for MRI of Brain Tumors
Current Pharmaceutical Biotechnology Virulence Mechanisms Displayed by Salmonella to Impair Dendritic Cell Function
Current Medicinal Chemistry Synthetic Inhibitors of Group IVA and Group VIA Phospholipase A2
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pitfalls and Solutions for the Validation of Novel Drugs in Animal Models of Disease
Current Immunology Reviews (Discontinued) Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression
Current Pharmaceutical Design